BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24488098)

  • 1. MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.
    Shostak K; Patrascu F; Göktuna SI; Close P; Borgs L; Nguyen L; Olivier F; Rammal A; Brinkhaus H; Bentires-Alj M; Marine JC; Chariot A
    Cell Death Differ; 2014 May; 21(5):811-24. PubMed ID: 24488098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
    Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
    Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2.
    Choy MK; Movassagh M; Bennett MR; Foo RS
    J Cell Physiol; 2010 Mar; 222(3):635-9. PubMed ID: 19950214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preconditioning-Activated AKT Controls Neuronal Tolerance to Ischemia through the MDM2-p53 Pathway.
    Barrio E; Vecino R; Sánchez-Morán I; Rodríguez C; Suárez-Pindado A; Bolaños JP; Almeida A; Delgado-Esteban M
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells.
    Singh S; Ramamoorthy M; Vaughan C; Yeudall WA; Deb S; Palit Deb S
    Cell Death Differ; 2013 Apr; 20(4):558-66. PubMed ID: 23238568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation.
    Feng J; Tamaskovic R; Yang Z; Brazil DP; Merlo A; Hess D; Hemmings BA
    J Biol Chem; 2004 Aug; 279(34):35510-7. PubMed ID: 15169778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
    J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT.
    Wang X; Yang Z; Zhang H; Ding L; Li X; Zhu C; Zheng Y; Ye Q
    Biochim Biophys Acta; 2008 Jun; 1783(6):1220-8. PubMed ID: 18302941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation.
    Brekman A; Singh KE; Polotskaia A; Kundu N; Bargonetti J
    Breast Cancer Res; 2011 Jan; 13(1):R3. PubMed ID: 21223569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
    Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
    Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents.
    Duong V; Boulle N; Daujat S; Chauvet J; Bonnet S; Neel H; Cavaillès V
    Cancer Res; 2007 Jun; 67(11):5513-21. PubMed ID: 17545634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt enhances Mdm2-mediated ubiquitination and degradation of p53.
    Ogawara Y; Kishishita S; Obata T; Isazawa Y; Suzuki T; Tanaka K; Masuyama N; Gotoh Y
    J Biol Chem; 2002 Jun; 277(24):21843-50. PubMed ID: 11923280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protein synthesis alters protein degradation through activation of protein kinase B (AKT).
    Dai CL; Shi J; Chen Y; Iqbal K; Liu F; Gong CX
    J Biol Chem; 2013 Aug; 288(33):23875-83. PubMed ID: 23843462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
    Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
    Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship and prognostic significance of phospho-(serine 166)-murine double minute 2 and Akt activation in node-negative breast cancer with regard to p53 expression.
    Schmitz KJ; Grabellus F; Callies R; Wohlschlaeger J; Otterbach F; Kimmig R; Levkau B; Schmid KW; Baba HA
    Virchows Arch; 2006 Jan; 448(1):16-23. PubMed ID: 16208531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
    Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
    Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
    Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
    J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
    Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
    Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer.
    Thirumurthi U; Shen J; Xia W; LaBaff AM; Wei Y; Li CW; Chang WC; Chen CH; Lin HK; Yu D; Hung MC
    Sci Signal; 2014 Jul; 7(336):ra71. PubMed ID: 25074979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.